Lexington ’s Inotek suggests it could explore sale after another trial flop

Lexington-based Inotek Pharmaceuticals said Friday it is exploring “strategic alternatives” — corporate shorthand for a possible sale or other major transaction — after its lead drug for glaucoma flunked another big study. Inotek (Nasdaq: ITEK) announced the failure of a Phase 2 study in which patients received the company’s drug, called trabodenoson, al ong with another glaucoma eye drop, Pfizer’s Xalatan. According to Inotek, patients saw a reduction in eye pressure after four weeks…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news